key: cord-0719891-sk8fkyvz authors: Cecchi, Nicola; Giannotta, Juri Alessandro; Barcellini, Wilma; Fattizzo, Bruno title: A case of severe aplastic anaemia after SARS‐CoV‐2 vaccination date: 2021-11-16 journal: Br J Haematol DOI: 10.1111/bjh.17947 sha: a7c1f2b26c47f1aa82a943521e369e25d5bb2096 doc_id: 719891 cord_uid: sk8fkyvz nan parvovirus B-19 IgG were positive (DNA negative). Autoimmune tests were all negative, including direct anti-globulin test (DAT), anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), p-and c-anti-neutrophil cytoplasmic antibodies (p-ANCA, c-ANCA). Bone marrow aspirate and biopsy showed 10% cellularity in absence of blasts or dysplastic features, and normal cytogenetics. Flow cytometry revealed the presence of a small PNH clone of 0Á6% on granulocytes and 0Á03% on erythrocytes. The diagnosis of severe AA (SAA) according to Camitta criteria was established, and the patient started on steroids (prednisone 1 mg/kg/day) and platelets transfusions with no response. Due to worsening pancytopenia (Hb 88 g/l, ANC 0.9 9 10 9 /l, PLT 10 9 10 9 /l) he was then referred to our Centre (May 2021) and treated with immunosuppressive therapy (IST, cyclosporin 3 mg/ kg/day + rabbit anti-thymocyte globulin, ATG). At 15 days after ATG, the patient developed fever and severe right knee arthritis interpreted as serum sickness and managed at first with high-dose steroids. Thereafter, synovial liquid culture turned positive for Pseudomonas aeruginosa, and CMV reactivation occurred, requiring intravenous antibiotic and anti-viral therapy, with progressive resolution of the clinical picture. At last follow-up the patient was still severely pancytopenic and transfusion-dependent (Hb 82 g/l, ANC 0Á58 9 10 9 /l, PLT 18 9 10 9 /l, after transfusion). This is the first patient developing AA after SARS-CoV-2 vaccine reported to date, although we cannot prove a causative relationship besides the temporal association. Compared to post-COVID-19 vaccine peripheral AICs, which are mainly due to humoral autoimmunity and were rapidly controlled by steroids, 1-4 our patient presented a severe cellular-mediated autoimmune condition, not responsive to first-line immunosuppression, and complicated by serum sickness and infections. This is in keeping with the known deeper immune dysregulation of AA, including the derangement of central immunity, and with the consequent heavier immunosuppressants utilised. However, the clinical outcome seems highly unpredictable, as the other reported patients post-HBV, H1N1 influenza, and varicella-zoster virus vaccines were both paediatric or adults experiencing either transient disease or severe refractory AA requiring bone marrow transplant. [9] [10] [11] [12] [13] [14] [15] This case highlights that AIC and AA may be secondary to undetected or disregarded triggers, such as infections, traumas, drugs, etc. Accordingly, COVID-19 infection has been associated with AIC and AA development/exacerbations, correspondence through several hypothesised mechanisms (i.e. molecular mimicry and aberrant over activation of humoral and cellular immunity) that may occur even after vaccination. [16] [17] [18] On the other hand, in our patient SARS-CoV-2 vaccine may have induced an immune activation that disclosed a latent autoimmunity. The presence of a PNH clone in our patient, as commonly observed in subjects with primary AA, favours the second pathogenic mechanism, although both hypotheses are not mutually exclusive. In our patient, AA developed 1 month after the last booster dose of SARS-CoV-2 vaccine, possibly suggesting a relationship, although difficult to demonstrate given the mass vaccinations for SARS-CoV-2 and the known incidence of AA. Additionally, causes of secondary AA other than SARS-CoV-2 infection/vaccine should not be disregarded, including other infections, drugs, and the rarer congenital bone marrow failures. In conclusion, SARS-CoV-2 vaccine may be associated with the development and/or exacerbation of both peripheral AICs and central AA, either as the single trigger or by disclosing a latent autoimmunity. Clinical awareness is fundamental to guide the evaluation of patients developing signs/ symptoms suggestive of cytopenias after SARS-CoV-2 vaccine and to promptly establish the diagnosis and treatment of even rare haematological conditions. In any case, the several reports of AIC and AA complications caused by COVID-19 infection should be taken into consideration when weighing the risks/benefits of COVID-19 vaccination. No funding sources to declare. A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease Exacerbation of immune thrombocytopenia following COVID-19 vaccination A case of immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination Can vaccination trigger autoimmune disorders? A meta-analysis. Vaccines (Basel) Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction Aplastic anemia following varicella vaccine Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation Severe pancytopenia triggered by recombinant hepatitis B vaccine Pancytopenia after recombinant hepatitis B vaccine-an Indian case report Case reports of aplastic anemia after vaccine administration Relapse of severe aplastic anaemia after influenza immunization Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes SARS-CoV-2 infection in aplastic anaemia. Haematologica. 2021 (Online ahead of print Are patients with autoimmune cytopenias at higher risk of COVID-19 pneumonia? The experience of a reference center in Northern Italy and review of the literature SARS-CoV-2 vaccination in patients with autoimmune cytopenias: the experience of a reference center All authors declare that they have no conflict of interest inherent to the present article to disclose. Bruno Fattizzo received consultancy from Apellis, Momenta, and Novartis and lecture fee/congress support from Alexion and Apellis. Wilma Barcellini received consultancy from Agios, Alexion, Apellis, Biocryst, Bioverativ, Incyte, Momenta, and Novartis; and lecture fee/congress support from Alexion, Incyte, Novartis, and Sanofi. All the authors followed patients, wrote the article, and revised it for important intellectual content.